PMID- 1336878
OWN - NLM
STAT- MEDLINE
DCOM- 19930225
LR  - 20061115
IS  - 0761-8425 (Print)
IS  - 0761-8425 (Linking)
VI  - 9 Suppl 4
DP  - 1992
TI  - [Do clinical and non-specific biological data influence staging?].
PG  - R305-8
AB  - Recent improvements in imaging technics have led many physicians to propose an 
      extensive work-up in non small cell lung carcinoma (NSCLC) without clear impact 
      on the therapeutic decisions. In fact, it appears that patients with operable 
      disease (stage I, II NSCLC) do not clearly benefit of such complete assessment in 
      absence of symptoms. In the same way, patients with established metastatic 
      disease (stage IV NSCLC) do not require an extensive work-up except when the 
      evidence of a metastatic lesion has a clear specific impact. On the other hand, 
      in case of locally advanced disease (stage III NSCLC), the decision of an 
      aggressive therapeutic approach including surgery, radiotherapy and chemotherapy 
      justify a complete assessment in order to control the lack of distant metastases.
FAU - Le Chevalier, T
AU  - Le Chevalier T
AD  - Institut Gustave-Roussy, Villejuif.
LA  - fre
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Les donnees cliniques et biologiques non specifiques influencent-elles le bilan 
      d'extension?
PL  - France
TA  - Rev Mal Respir
JT  - Revue des maladies respiratoires
JID - 8408032
SB  - IM
MH  - Carcinoma, Non-Small-Cell Lung/*pathology/secondary/surgery
MH  - Humans
MH  - Lung Neoplasms/*pathology/surgery
MH  - Neoplasm Staging
MH  - Prognosis
RF  - 18
EDAT- 1992/01/01 00:00
MHDA- 1992/01/01 00:01
CRDT- 1992/01/01 00:00
PHST- 1992/01/01 00:00 [pubmed]
PHST- 1992/01/01 00:01 [medline]
PHST- 1992/01/01 00:00 [entrez]
PST - ppublish
SO  - Rev Mal Respir. 1992;9 Suppl 4:R305-8.